EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

In silico analysis for the proposal of new drugs against the phosphoprotein nucleocapsid of the severe acute respiratory syndrome coronavirus 2 virus

Amanda Bubula de Souza, Leonardo Pereira de Araújo, Amanda Almeida Morais, Leandro Marcos Santos, Yana Cristina Albanez Santos, Cássia Milene Ribeiro Lopes, Paulo Vinicius Sanches Daltro de Carvalho, Syed Shah Hassan, Nelson José Freitas da Silveira

Innovative Medicines & Omics · 2024

DOI: 10.36922/imo.3731 ↗

At a glance

Journal article in Innovative Medicines & Omics, 2024. Written by Amanda Bubula de Souza and 8 co-authors. Cited 1 times so far (Crossref). The full text is freely available (open access, CC BY-NC 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which began in late 2019, has resulted in approximately seven million deaths worldwide. This underscores the urgent need for vaccine and drug development. In silico techniques, especially molecular docking, provide promising means for discovering new treatments. This study aimed to identify novel compounds with potential activity against the nucleocapsid protein of SARS-CoV-2 using drug repositioning and bioisosterism techniques. We performed molecular docking with 20,115 compounds from the BindingDB database. The protein, obtained from the Protein Data Bank (PDB ID: 6WZQ), was prepared using MGLTools software, including protonation and removal of co-crystallized ligands and water molecules. We defined the binding site at the protein’s active site and used AutoDock Vina software for molecular docking, ranking the results based on relative binding energy. Interactions were visualized using Pymol and LigPlot+ software, focusing on hydrogen bonds and hydrophobic interactions. Compound BDBM6732 showed the most favorable binding energy (−13.4 kcal/mol), similar to the control compound suramin (−13.3 kcal/mol), but it was predicted to carry risks for hepatotoxicity and mutagenesis. We generated bioisosteres, resulting in two candidate analog compounds with superior affinity to four compounds referenced in the scientific literature, two of which had their activity validated in in vivo testing. These results suggest that the two analogs may potentially combat SARS-CoV-2 by binding to the nucleocapsid protein. However, validation in both in vitro and in vivo settings is essential.

Cite

APA

Souza, A. B. D., Araújo, L. P. D., Morais, A. A., Santos, L. M., Santos, Y. C. A., Lopes, C. M. R., Carvalho, P. V. S. D. D., Hassan, S. S., & Silveira, N. J. F. D. (2024). In silico analysis for the proposal of new drugs against the phosphoprotein nucleocapsid of the severe acute respiratory syndrome coronavirus 2 virus. Innovative Medicines & Omics. https://doi.org/10.36922/imo.3731

Vancouver

Souza ABD, Araújo LPD, Morais AA, Santos LM, Santos YCA, Lopes CMR, et al. In silico analysis for the proposal of new drugs against the phosphoprotein nucleocapsid of the severe acute respiratory syndrome coronavirus 2 virus. Innovative Medicines & Omics. 2024. doi:10.36922/imo.3731

BibTeX
@article{Souza2024,
  author = {Souza, Amanda Bubula de and Araújo, Leonardo Pereira de and Morais, Amanda Almeida and Santos, Leandro Marcos and Santos, Yana Cristina Albanez and Lopes, Cássia Milene Ribeiro and Carvalho, Paulo Vinicius Sanches Daltro de and Hassan, Syed Shah and Silveira, Nelson José Freitas da},
  title = {In silico analysis for the proposal of new drugs against the phosphoprotein nucleocapsid of the severe acute respiratory syndrome coronavirus 2 virus},
  journal = {Innovative Medicines & Omics},
  year = {2024},
  doi = {10.36922/imo.3731}
}
Start for free →